US FDA approves KalVista's oral swelling disorder drug, shares rise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 07 2025
0mins
Source: Reuters
FDA Approval of Ekterly: KalVista Pharmaceuticals received FDA approval for Ekterly, the first on-demand oral treatment for hereditary angioedema, leading to an 18% increase in its stock price. The drug is expected to be available by mid-July at a wholesale cost of $16,720 per dose.
Market Impact and Sales Projections: The introduction of Ekterly is anticipated to significantly boost the U.S. on-demand HAE market, with projections estimating sales growth to $1.2 billion by 2030, and peak sales of over $750 million for Ekterly due to its convenience compared to existing treatments.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 34.38 USD with a low forecast of 29.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.540
Low
29.00
Averages
34.38
High
39.00
Current: 16.540
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
